Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > 3-aminolevamisole

3-aminolevamisole

3-aminolevamisole is a synthetic compound that has been studied for its potential use in medical research and applications.
It is a derivative of the antiparasitic drug levamisole, and has been investigated for its effects on various biological processes, including immune function and metabolic pathways.
PubCompare.ai's innovative AI-powered tool helps researchers optimize 3-aminolevamisole research by enhancing reproducibility and accuracy, enabling them to locate the best protocols from literature, pre-prints, and patents.
This improves the quality and efficiency of 3-aminolevamisole research, contributing to advancements in our understanding of its pharmacological properties and potential therapeutic applications.

Most cited protocols related to «3-aminolevamisole»

1
Enrichment Analysis of Known Disease Genes
Cited 30 times
Relative to recent association studies, the WTCCC has a small sample size (~2,000 cases and ~3,000 controls per disease). Thus, even with our novel method and a reduced multiple testing burden, our ability to detect numerous novel gene associations may be limited. Alternatively, we tested each disease for an enrichment of known disease genes identified from the NHGRI GWAS Catalog25 (link). For each disease, we used the reported genes from the GWAS catalog as the set of known disease genes. We excluded studies listed in the NHGRI GWAS catalog that included the WTCCC samples in order to make sure our known gene lists were independent from the current analysis. We then counted the number of known disease genes that had a PrediXcan p-value below a given threshold. We compared this to the null expectation based on 10,000 randomly drawn gene sets of similar size to the known disease gene set to derive an enrichment p-value. We tested enrichment using PrediXcan p-value thresholds of 0.05 and 0.01.
Gamazon E.R., Wheeler H.E., Shah K.P., Mozaffari S.V., Aquino-Michaels K., Carroll R.J., Eyler A.E., Denny J.C., Nicolae D.L., Cox N.J, & Kyung Im H. (2015). A gene-based association method for mapping traits using reference transcriptome data. Nature genetics, 47(9), 1091-1098.
Publication 2015
3-aminolevamisole Genes Genome-Wide Association Study Hereditary Diseases Multiple Birth Offspring N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide
2
Immunochip Genotyping of IBD Cohorts
Cited 16 times
Recruitment of patients and matched controls genotyped with the Immunochip was performed in 15 countries in Europe, North America and Oceania (Table 1). Diagnosis of IBD was based on accepted radiologic, endoscopic, and histopathologic evaluation. All included cases fulfill clinical criteria for IBD. Genotyping was performed across 36 batches, and included a total of 19,802 Crohn's disease cases, 14,864 ulcerative colitis cases and 34,872 population controls. The Immunochip cohort includes 3,424 Crohn's disease cases, 3,189 ulcerative colitis cases and 7,379 population controls present in the GWAS cohort. The overlapping Immunochip samples were excluded for the trans-ethnic association analysis but included in the modelling of European vs non-European IBD because this was based solely on Immunochip data.
Liu J.Z., van Sommeren S., Huang H., Ng S.C., Alberts R., Takahashi A., Ripke S., Lee J.C., Jostins L., Shah T., Abedian S., Cheon J.H., Cho J., Dayani N.E., Franke L., Fuyuno Y., Hart A., Juyal R.C., Juyal G., Kim W.H., Morris A.P., Poustchi H., Newman W.G., Midha V., Orchard T.R., Vahedi H., Sood A., Sung J.Y., Malekzadeh R., Westra H.J., Yamazaki K., Yang S.K., Barrett J.C., Alizadeh B.Z., Parkes M., BK T., Daly M.J., Kubo M., Anderson C.A, & Weersma R.K. (2015). Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature genetics, 47(9), 979-986.
Publication 2015
3-aminolevamisole Crohn Disease Diagnosis Endoscopy Europeans Genome-Wide Association Study Ulcerative Colitis
3
Validating Microbiome-Based CRC Prediction
Cited 15 times
We built a validation LODO model trained on MetaPhlAn2 taxonomic abundances from the previously described set of 7 cohorts and applied it to the independent validation cohorts. To test the performance of the model when challenged with other diseases, we selected 4 metagenomic cohorts 52 (link)–55 (link) covering 3 non-CRC diseases (ulcerative colitis - UC, Crohn’s disease - CD, and type-2 diabetes - T2D) and we used them for further experiments. For each disease (UC, CD, T2D) in each dataset, we randomly drawn 60 samples from the control class as well as 60 samples from the cases and added them to each validation dataset in turn, labelled as controls. The random selection was repeated ten times, and the validation AUC computed on the model’s prediction accordingly. The rationale is to observe the decrease in AUC when the external cases are added to the controls of the validation cohort with respect the addition of healthy controls.
Specificity of the prediction model was also assessed by the addition of 13 IBD samples to Cohort1: we used the 13 samples either as controls for Cohort1 or added to the original controls; we performed a cross-validation and a LODO on Cohort1 (no validation cohorts in the training) using MetaPhlAn2 microbial species.
To assess the prediction ability of our Random Forest approach with respect to more traditional non-invasive tests like the FOBT and the Wif-1 Methylation test, we recorded the true positive rate (sensitivity) and the false positive rate (1 - specificity) for a subset of the ZellerG_2014 cohort according to these two tests and one-hundred positive detection thresholds in the case of Random Forest models. We then combined the Random Forest approach with the two tests in turn, first assigning the positive class when both predictors are positive (“AND” model) secondly when just one predictor is (“OR” model).
Thomas A.M., Manghi P., Asnicar F., Pasolli E., Armanini F., Zolfo M., Beghini F., Manara S., Karcher N., Pozzi C., Gandini S., Serrano D., Tarallo S., Francavilla A., Gallo G., Trompetto M., Ferrero G., Mizutani S., Shiroma H., Shiba S., Shibata T., Yachida S., Yamada T., Wirbel J., Schrotz-King P., Ulrich C.M., Brenner H., Arumugam M., Bork P., Zeller G., Cordero F., Dias-Neto E., Setubal J.C., Tett A., Pardini B., Rescigno M., Waldron L., Naccarati A, & Segata N. (2019). Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nature medicine, 25(4), 667-678.
Publication 2019
3-aminolevamisole Crohn Disease Hypersensitivity Metagenome Methylation Ulcerative Colitis
4
Multicenter Study of SLE Disease Activity
Cited 14 times
This was a multicenter cross-sectional study involving 8 centers in the UK. All patients included in the study were diagnosed as having SLE according to the American College of Rheumatology criteria (5 (link),6 (link)). Patients were excluded from the study if they were pregnant, <18 years of age, or unable to give valid consent. This study was carried out in accordance with the Helsinki Declaration and received multicenter research approval from the Hull and East Riding Research Ethics Committee (Hull, UK) as well as approval from the local research ethics committees of all participating centers. Written consent was obtained from all patients.
The study was conducted from March 2005 to August 2006. At every assessment, data on disease activity, investigations, and treatment were collected. Disease activity was assessed using the BILAG-2004 index, Classic BILAG index, and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) (7 (link)). All clinicians involved in this study had been trained to use all 3 disease activity indices. More than 1 assessment was obtained on the majority of patients during the study period.
Yee C.S., Farewell V., Isenberg D.A., Rahman A., Teh L.S., Griffiths B., Bruce I.N., Ahmad Y., Prabu A., Akil M., McHugh N., D'Cruz D., Khamashta M.A., Maddison P, & Gordon C. (2007). British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis and Rheumatism, 56(12), 4113-4119.
Full text: Click here
Publication 2007
3-aminolevamisole Ethics Committees, Research Lupus Erythematosus, Systemic Patients
5
Prioritizing Animal Disease Research Protocols
Cited 13 times
The working groups of the DISCONTOOLS project were created by inviting stakeholders to become involved in WP2, WP3 and/or WP4 with the PMB taking care of WP1 and WP5 (see Fig. 1). In parallel, the PMB invited an expert to Chair each of WP2, WP3 and WP4. The WPs then established a list of 52 priority diseases to be included in the prioritisation exercise. The starting point for the list of diseases was from the Action Plan of the ETPGAH which referred to 47 diseases. In addition, it was considered important not to lose sight of endemic diseases or disease syndromes (e.g. internal parasites, mastitis). Therefore, 3 groups of diseases were defined as follows:

epizootic diseases: infectious diseases which pose a risk for introduction or spread in the EU and for which tools for optimum detection, surveillance and control would be beneficial;

food producing animal complexes: major enzootic diseases of livestock in Europe;

zoonotic diseases: infectious diseases of animals that are important for human health and for their socio-economic effects.

The geographic dimension of the project was primarily European. Naturally, where a disease was not present in Europe, a global perspective was taken into account. The expert groups were asked to highlight and take into account strains and species where the economic impact was the highest not only in Europe, but worldwide.
After discussions of the working groups of DISCONTOOLS a final list of 52 diseases was agreed. The list was not considered to be exhaustive, but representative of most disease scenarios. Infectious diseases of aquatic animals or companion animals without a zoonotic implication were not considered.
O’Brien D., Scudamore J., Charlier J, & Delavergne M. (2017). DISCONTOOLS: a database to identify research gaps on vaccines, pharmaceuticals and diagnostics for the control of infectious diseases of animals. BMC Veterinary Research, 13, 1.
Full text: Click here
Publication 2016
3-aminolevamisole Animals Communicable Diseases Endemic Diseases Europeans Feeds, Animal Homo sapiens Livestock Mastitis N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide Parasites Pets Strains Syndrome Vision Zoonoses

Most recents protocols related to «3-aminolevamisole»

1
Disease Activity States for ASDAS Score
Four disease activity states for the ASDAS score have been defined: The ASDAS assessment measures four disease activity states: inactive, moderate, high, and very high. Disease status was evaluated on the basis of three cutoff values: 1.3, 2.1, and 3.5 units. The 3 cut-offs selected to separate these states were: < 1.3 between "inactive disease" and "moderate disease activity", < 2.1 between "moderate disease activity" and "high disease activity", and > 3.5 between "high disease activity" and "very high disease activity". The following cutoff values were selected to indicate improvement: a change of ≥ 1.1 units denoted a clinically important improvement, and a change of ≥ 2.0 units denoted a major improvement15 (link)–18 (link).
Huang P.J., Chen Y.H., Huang W.N., Chen Y.M., Lai K.L., Hsieh T.Y., Hung W.T., Lin C.T., Tseng C.W., Tang K.T., Chou Y.Y., Wu Y.D., Huang C.Y., Hsieh C.W., Chen Y.J., Liao Y.W., Liu Y.T, & Chen H.H. (2023). The electronic medical record management systems may improve monitoring and control of disease activity in patients with ankylosing spondylitis. Scientific Reports, 13, 3957.
Full text: Click here
Publication 2023
3-aminolevamisole N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide
2
Severe COVID-19 Pneumonia Outcome Analysis
In this analysis, we included patients with COVID-19 pneumonia who were
discharged (or died) between 5 January 2020 and 3 March 2020 at Huangshi City
Infectious Disease Hospital of Hubei Province. According to their condition at
admission and with reference to the Novel Coronavirus Pneumonia Diagnosis and
Treatment Program (Sixth Edition),4 all included patients met
the diagnostic criteria for severe or critically severe COVID-19 pneumonia. The
diagnostic criteria for severe COVID-19 pneumonia were meeting any of the
following: 1) respiratory distress, with respiration rate >30 breaths/minute;
2) oxygen saturation at rest <93%; and 3) arterial blood oxygen partial
pressure (PaO2)/oxygen uptake concentration (FiO2) ≤300 mmHg. The diagnostic
criteria for critically severe COVID-19 pneumonia were meeting one of the
following conditions: 1) respiratory failure requiring mechanical ventilation;
2) shock; and 3) other organ failure requiring monitoring and treatment in the
intensive care unit (ICU). All enrolled patients were tested in the local
disease prevention and control department and were positive for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid in more than two
nasopharyngeal swabs. The exclusion criteria were as follows: 1) age <18
years; 2) tracheal intubation and invasive mechanical ventilation within 24
hours of admission; and 3) death within 24 hours of admission.
Zhu Y., Chen D., Zhu Y., Ge X., Li Z, & Miao H. (2023). Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia. The Journal of International Medical Research, 51(2), 03000605221149292.
Publication 2023
3-aminolevamisole Arteries Coronavirus COVID 19 Diagnosis Intubation, Intratracheal Mechanical Ventilation N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide Nucleic Acids Oxygen Oxygen Saturation Patients Pneumonia Respiratory Failure Respiratory Rate SARS-CoV-2 Shock Syndrome
3
Artificial Panicle Blast Resistance Identification
The artificial identification of panicle blast resistance in the field was performed as described previously [2 (link)] using the mixed conidial suspensions (MCSs) containing five or six M. oryzae isolates. Isolates were mixed in equal proportions to form a conidial suspension of 30–40 conidia per field of view under a 10 × 10 microscope. All rice cultivars/lines were planted in Xinminzhou Lingang Industrial Park, Jingkou District, Zhenjiang City, Jiangsu Province, China. Each line contained 6 rows with 10 plants per row and a row spacing of 11.1 × 30 cm in a randomized complete block design. Artificial inoculation was carried out at the booting stage, and 5 tillers each line were injected with 1 mL conidial suspension of each MCS. Disease scores were rated at rice ripening stage according to the Technical Specification for Identification and Evaluation of Blast Resistance in Rice Variety Regional Test (NY/T 2646-2014) issued by the Ministry of Agriculture and Rural Affairs of the People’s Republic of China. According to their disease scores, each rice line was then classified into different resistant levels: highly resistant (0 ≤ disease grade < 1), resistant (1.0 ≤ disease grade < 3), moderately resistant (3.0 ≤ disease grade < 5.0), moderately susceptible (5.0 ≤ disease grade < 7.0), susceptible (7.0 ≤ disease grade < 9.0), and highly susceptible (disease grade = 9.0). On the basis of the disease scores of each panicle, the final disease grade of the variety was determined as follows: (1) If the disease grades of 5 inoculated panicles ranged less than 2, then the highest disease grade of the 5 inoculated panicles was used as the final disease grade of the variety. (2) If the 5 disease grades ranged more than 3 and the panicles with relatively high disease grades constituted the majority, then the highest disease grade of the 5 inoculated panicles was designated as the final disease grade of the variety. (3) If the 5 disease grades ranged more than 3 and the panicles with relatively low disease grades accounted for the majority, then the second disease grade of the 5 inoculated panicles from top to bottom was used as the final disease grade of the variety.
Gao P., Li M., Wang X., Xu Z., Wu K., Sun Q., Du H., Younas M.U., Zhang Y., Feng Z., Hu K., Chen Z, & Zuo S. (2023). Identification of Elite R-Gene Combinations against Blast Disease in Geng Rice Varieties. International Journal of Molecular Sciences, 24(4), 3984.
Full text: Click here
Publication 2023
3-aminolevamisole Conidia Microscopy Oryza sativa Plants Vaccination
4
Retinopathy of Prematurity Screening Protocol
According to the ROP screening, preterm infants included in the study (≤ 33 weeks of gestational age, ≤ 1800 g of birth weight or assessed by the neonatologist as at high risk of ROP) [14 (link)] underwent a series of eye fundus examinations with binocular indirect ophthalmoscopy. The examinations started from the 4th week of chronological age and were performed every 7–10 days, depending on retinal vascularization and the presence of fundus lesions. The diagnosis of ROP was made when ROP vascular features were found at the junction of vascularized and avascular retina. In accordance with the International Classification of Retinopathy of Prematurity (ICROP), they were classified as ROP stages, including demarcation line (stage 1), ridge (stage 2), extraretinal neovascular proliferation (stage 3), then partial or total retinal detachment (stage 4 and 5) [15 ], [16 ]. Additionally, other important features were described in ROP cases, including zone and presence of plus disease.
According to the Early Treatment for Retinopathy of Prematurity guidelines, patients diagnosed with ROP were qualified for treatment in the case of any stage of ROP in zone I with plus disease, stage 3 ROP with no plus disease in zone I, or stage 2 or 3 ROP with the plus disease in zone II [17 ]. These patients were treated by laser photocoagulation of the peripheral avascular retina or intravitreal administration of anti-VEGF antibody (ranibizumab), within 72 h after the diagnosis. In one patient (2 eyes), anti-VEGF therapy was used as the second line of treatment after laser photocoagulation.
The screening was finished in patients with retinal vascularization reaching zone III or regression of ROP on at least two examinations.
Choręziak-Michalak A., Gotz-Więckowska A., Chmielarz-Czarnocińska A., Seremak-Mrozikiewicz A, & Szpecht D. (2023). Potential role of eNOS and EDN-1 gene polymorphisms in the development and progression of retinopathy of prematurity. BMC Ophthalmology, 23, 78.
Full text: Click here
Publication 2023
3-aminolevamisole Antibodies, Anti-Idiotypic Birth Weight Blood Vessel Diagnosis Eye Fundus Oculi Gestational Age Light Coagulation N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide Neonatologists Ophthalmoscopy Pathologic Neovascularization Patients Physical Examination Preterm Infant Ranibizumab Retina Retinal Detachment Retinal Neovascularization Vascular Endothelial Growth Factors
5
Genetic Profiling of 21-OHD CAH
This study was approved by the National Institutes of Health Institutional Review Board. All subjects were enrolled in an ongoing Natural History Study at the National Institutes of Health Clinical Center in Bethesda, MD, USA (NCT00250159). The cohort was composed of a total of 278 subjects (145 affected patients of 21-OHD CAH, 116 carriers of 21-OHD CAH, 3 normal relatives from 135 families, and 11 affected patients and 3 relatives of other diseases such as EDS, XY disorder of sex development and other CAH types from 11 families). All adult subjects or parents of children (<18 years old) gave written informed consent. Clinical evaluations for the diagnosis of CAH and EDS were completed as described previously [7 (link)]. All subjects had comprehensive genetic records, including a complete CAH and CAH-X genotype by a CLIA-accredited laboratory (PreventionGenetics, LLC, Marshfield, WI), as well as copy numbers of TNXB exons 35, 40, C4A, C4B genes determined as previously described [10 (link),32 (link),33 (link)]. For each subject, TNXA copy number was determined as “CTNXA = CC4A + CC4B − 2”, with 2 accounting for TNXB and/or CAH-X chimeras if applicable. For the analysis of TNXA locus homologous to TNXB exon 40, allele-specific PCR was conducted with the primer pair of 5′-GACCCAGAAACTCCAGGTGGGAG-3′ and 5′-CACCGAGAACTCGAAGCCCTTC-3′, followed by Sanger sequencing with primer 5′-CAATGAGGCCCTGCACAGC-3′. NC_000006.12 (Chr6: 32,008,420–32,013,023, complement) and NC_000006.12 (chr6: 32,041,153–32,109,338, complement) were used as reference for TNXA and TNXB, respectively. DNASTAR Lasergene (Madison, WI, USA) was used for sequence alignment analysis.
Lao Q., Zhou K., Parker M., Faucz F.R, & Merke D.P. (2023). Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X. Genes, 14(2), 265.
Full text: Click here
Publication 2023
3-aminolevamisole Adult Alleles Child Chimera Diagnosis Disorders of Sex Development Ethics Committees, Research Exons Genes Genotype N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide Oligonucleotide Primers Parent Patients Sequence Alignment

Top products related to «3-aminolevamisole»

1
α e4000 columns by Tosoh
The α-e4000 columns are used for high-performance liquid chromatography (HPLC) applications. They feature a silica-based stationary phase designed for the separation and purification of a variety of organic compounds. The columns provide efficient and reliable performance for analytical and preparative-scale separations.
2
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
3
Carbo free blocking solution by Vector Laboratories
Sourced in United States, Canada
Carbo-Free Blocking Solution is a ready-to-use reagent designed to block non-specific binding in immunoassays. It is a protein-free, carbohydrate-based solution that effectively reduces background signal to enhance the specificity of target detection.
4
7900ht fast real time pcr system by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Japan, Italy, Canada, Switzerland, Singapore, Spain, Denmark, Belgium, Netherlands, France, Poland
The 7900HT Fast Real-Time PCR System is a laboratory instrument designed for fast and accurate real-time PCR analysis. It features a 96-well format, support for multiple fluorescent dyes, and rapid thermal cycling capabilities.
5
Sec tsk gel α 3000 by Tosoh
The SEC TSK-GEL α-3000 is a size exclusion chromatography (SEC) column used for the separation and analysis of macromolecules. It is designed to provide high-resolution separation of proteins, polymers, and other large molecules based on their size and molecular weight.
6
Bluefuse multi v4 by Illumina
Sourced in United States
BlueFuse Multi v4.4 is a software platform developed by Illumina for the analysis and interpretation of cytogenomic microarray data. It provides a comprehensive suite of tools for the detection and visualization of chromosomal aberrations, copy number variations, and genotype information from various types of microarray experiments.
7
Amaxa nucleofector system by Lonza
Sourced in United States, Switzerland, Germany, France
The Amaxa Nucleofector system is a laboratory instrument designed for the efficient transfection of various cell types, including primary cells and hard-to-transfect cell lines. The system utilizes electroporation technology to facilitate the introduction of nucleic acids, such as plasmids, siRNA, or mRNA, into the target cells.
8
Nanodrop 1000 spectrophotometer by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Australia, Spain, China, Japan, Italy, France, Canada, Denmark, Switzerland, Sweden, Belgium, Singapore, Ireland, Brazil, Taiwan, Province of China, New Zealand, Portugal, Saudi Arabia
The NanoDrop 1000 spectrophotometer is a compact, single-sample instrument designed for the quantification and analysis of DNA, RNA, and protein samples. It utilizes a patented sample retention system that requires only 1-2 microliters of sample to perform measurements.
9
Normal goat serum (ngs) by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, Australia, France, Macao, Sweden, Japan, Switzerland
Normal goat serum is a laboratory reagent derived from the blood of healthy goats. It is used as a blocking agent in various immunoassay techniques, such as Western blotting and immunohistochemistry, to prevent non-specific binding of antibodies.
10
Qiaamp dna mini kit by Qiagen
Sourced in Germany, United States, France, United Kingdom, Netherlands, Spain, Japan, China, Italy, Canada, Switzerland, Australia, Sweden, India, Belgium, Brazil, Denmark
The QIAamp DNA Mini Kit is a laboratory equipment product designed for the purification of genomic DNA from a variety of sample types. It utilizes a silica-membrane-based technology to efficiently capture and purify DNA, which can then be used for various downstream applications.

More about "3-aminolevamisole"

3-Aminolevamisole is a synthetic compound that has been extensively studied for its potential use in medical research and applications.
It is a derivative of the antiparasitic drug levamisole and has been investigated for its effects on various biological processes, including immune function, metabolic pathways, and more.
The compound has garnered significant interest in the scientific community due to its unique pharmacological properties.
Researchers have utilized cutting-edge tools like PubCompare.ai's innovative AI-powered platform to optimize 3-aminolevamisole research, enhancing reproducibility and accuracy.
This platform helps researchers locate the best protocols from literature, pre-prints, and patents, improving the quality and efficiency of 3-aminolevamisole research.
Synonyms for 3-aminolevamisole include 3-AL, 3-amino levamisole, and 3-amino-6-phenylimidazo[2,1-b]thiazole.
Related terms and abbreviations include levamisole (LMS), antiparasitic drugs, immune function, metabolic pathways, and pharmacological properties.
Subtopics of interest in 3-aminolevamisole research may include its mechanisms of action, therapeutic potential in various medical conditions, and its interactions with other compounds or biological systems.
Researchers may also explore the use of analytical tools like α-e4000, SAS 9.4, Carbo-Free Blocking Solution, 7900HT Fast Real-Time PCR System, SEC TSK-GEL α-3000, BlueFuse Multi v4.4, Amaxa Nucleofector system, NanoDrop 1000 spectrophotometer, and Normal goat serum to enhance their understanding and investigation of this compound.
By leveraging the insights gained from MeSH term descriptions and metadescriptions, as well as incorporating relevant information and tools, researchers can optimize their 3-aminolevamisole studies, leading to advancements in our understanding of its pharmacological properties and potential therapeutic applications.